We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03 | 1.39% | 2.19 | 2.10 | 2.24 | 2.19 | 2.11 | 2.11 | 301,853 | 09:52:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.92 | 7.3M |
TIDMIMM
RNS Number : 0304Q
Immupharma PLC
24 February 2016
24 FEBRUARY 2016
ImmuPharma PLC
Issue of Equity
Successful placing provides funding for completion of Phase III Lupuzor(TM) Trial
ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce the issue and allotment of 30,302,217 new ordinary shares of 10 pence each ("New Ordinary Shares"), raising GBP7.7 million in connection with the Placing and Subscription, as announced on 5 February 2016 (the "Placing and Subscription Announcement").
Furthermore, as outlined in the Placing and Subscription Announcement, the Company has applied to HM Revenue and Customs to receive VCT Advance Assurance and / or EIS Advance Assurance but, as of the date of this announcement, the Advance Assurances have not yet been received. The issue of any EIS Shares and the VCT Shares within the Placing, amounting to 2,856,539 Ordinary Shares which would raise a further GBP0.7 million for the Company (raising in aggregate GBP8.4 million, as announced in the Placing and Subscription Announcement), is conditional upon the Advance Assurances being obtained by not later than 23 March 2016. The Company intends to issue and allot the EIS Shares and VCT Shares provided the Advance Assurances are received by that date. A further update will be provided in due course.
Application will be made to the London Stock Exchange plc for the admission of the 30,302,217 New Ordinary Shares to trading on AIM. Admission is expected to take place at 8 a.m. on 25 February 2016 (or such later date as Panmure Gordon and the Company may agree, being not later than 8 a.m. on 24 March 2016) at which time the Placing and Subscription will become unconditional (save with regard to the EIS Shares and the VCT Shares). Dealings in the New Ordinary Shares on AIM will commence at the same time. The New Ordinary Shares will be issued credited as fully paid and will be identical to, and rank pari passu in all respects with, the Existing Ordinary Shares, including the right to all dividends and other distributions declared, made or paid in respect of the Existing Ordinary Shares following the date of Admission.
Following the issue of the New Ordinary Shares referred to above, ImmuPharma will have 118,924,680 Ordinary Shares in issue. No Ordinary Shares are held in treasury. Shareholders may use the above figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under section 5 of the FCA's Disclosure and Transparency Rules.
For further information please see the Company's website, www.immupharma.org, or contact:
ImmuPharma plc + 44 (0) 20 7152 Tim McCarthy, Chairman 4080 Lisa Baderoon, Head of Investor + 44 (0) 7721 413496 Relations lisa.baderoon@immupharma.com Panmure Gordon (Financial Adviser, Nominated Adviser & Broker) Fred Walsh, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking +44 (0) 20 7886 2500
All defined terms used in this announcement are defined, unless otherwise defined here, in the appendix to the Proposed Placing and Subscription and Notice of General Meeting announcement made on 5 February 2016.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEEAAALADLKEFF
(END) Dow Jones Newswires
February 24, 2016 07:35 ET (12:35 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions